Omaveloxolone approved for patients aged 16 years and older with Friedreich ataxia (FRDA): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
| dc.contributor.author | Lenahan, Arthur | |
| dc.contributor.author | Yano, Sho | |
| dc.contributor.author | Graham, Brett | |
| dc.contributor.author | Sen, Kuntal | |
| dc.contributor.author | ACMG Therapeutics Committee | |
| dc.contributor.department | Medical and Molecular Genetics, School of Medicine | |
| dc.date.accessioned | 2025-01-28T13:02:33Z | |
| dc.date.available | 2025-01-28T13:02:33Z | |
| dc.date.issued | 2023-09-09 | |
| dc.eprint.version | Final published version | |
| dc.identifier.citation | Lenahan A, Yano S, Graham B, Sen K; ACMG Therapeutics Committee5∗documents@acmg.net. Omaveloxolone approved for patients aged 16 years and older with Friedreich ataxia (FRDA): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). Genet Med Open. 2023;1(1):100832. Published 2023 Sep 9. doi:10.1016/j.gimo.2023.100832 | |
| dc.identifier.uri | https://hdl.handle.net/1805/45538 | |
| dc.language.iso | en_US | |
| dc.publisher | Elsevier | |
| dc.relation.isversionof | 10.1016/j.gimo.2023.100832 | |
| dc.relation.journal | Genetics in Medicine Open | |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
| dc.source | PMC | |
| dc.subject | Friedreich ataxia | |
| dc.subject | Neuromuscular medicine | |
| dc.subject | Omaveloxolone | |
| dc.subject | Orphan drug | |
| dc.subject | Precision medicine | |
| dc.title | Omaveloxolone approved for patients aged 16 years and older with Friedreich ataxia (FRDA): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG) | |
| dc.type | Article |